ASB17 Facilitates the Burst of LPS-Induced Inflammation Through Maintaining TRAF6 Stability

Pin Wan†, Ge Yang‡, Simeng Zhang†, Yaru Zhang†, Yaling Jia†, Xu Che†, Zhen Luo†, Pan Pan‡, Geng Li†, Xulin Chen†, Qiwei Zhang†, Wen Zhang‡, Qiuping Tan§, Yongkui Li†,§* and Jianguo Wu†,§*,†*

1 Guangdong Provincial Key Laboratory of Virology, Institute of Medical Microbiology, Jinan University, Guangzhou, China, 2 State Key Laboratory of Virology, College of Life Sciences, Wuhan University, Wuhan, China, 3 Foshan Institute of Medical Microbiology, Foshan, China, 4 The First Affiliated Hospital of Jinan University, Jinan University, Guangzhou, China, 5 Guangdong Longfan Biological Science and Technology, Foshan, China

ASB17, a member of the ankyrin repeat and SOCS box-containing protein (ASB) family, has been supposed to act as an E3 ubiquitin ligase. Actually, little is known about its biological function. In this study, we found that ASB17 knocking-out impaired the expression of the pro-inflammatory cytokines CCL2 and IL-6 in bone marrow-derived dendritic cells (BMDCs) stimulated by lipopolysaccharide (LPS), indicating an inflammation-promoting role of this gene. We reveal that ASB17 promotes LPS-induced nuclear factor kappa B (NF-κB) signal activation through interacting with TNF receptor-associated factor 6 (TRAF6) which is a crucial adaptor protein downstream of toll-like receptors (TLR). ASB17 via its aa177–250 segment interacts with the Zn finger domain of TRAF6. The interaction of ASB17 stabilizes TRAF6 protein through inhibiting K48-linked TRAF6 polyubiquitination. Therefore, we suggest that ASB17 facilitates LPS-induced NF-κB activation by maintaining TRAF6 protein stability. The inflammation enhancer role of ASB17 is recognized here, which provides new understanding of the activation process of inflammation and immune response.

Keywords: ASB17, NF-κB, TRAF6, K48-linked polyubiquitination, inflammatory cytokine

INTRODUCTION

The ankyrin repeat and suppressor of cytokine signaling (SOCS) box-containing protein (ASB) family containing 18 members has been identified as an E3 ubiquitin ligase family (Kohroki et al., 2005; Liu et al., 2019). ASB1, ASB2, and ASB12 have been found to form complexes respectively with Cullin5–Rbx2 and have E3 Ub ligase activity (Kohroki et al., 2005). ASB7 ubiquitinates DDA3 for degradation to regulate spindle dynamics and genome integrity (Uematsu et al., 2016). ASB9 targets ubiquitous mitochondrial creatine kinase (uMtCK) and negatively regulates cell growth (Kwon et al., 2010). ASB7 ubiquitinates DDA3 for degradation to regulate spindle dynamics and genome integrity (Uematsu et al., 2016). ASB9 targets ubiquitous mitochondrial creatine kinase (uMtCK) and negatively regulates cell growth (Kwon et al., 2010). ASB11 mediates BIK ubiquitination and degradation to determine cell fate during different cellular stresses (Chen et al., 2019). Like other members of the ASB family, ASB17 protein contains two ankyrin repeats and one SOCS box (Guo et al., 2004). We recently reported that ASB17 mediates cell apoptosis in the testsis by ubiquitylating and degrading BCLW and MCL1 (Yang et al., 2021). Through a study with ASB17 KO mice, we found that ASB17 was involved in cytokine regulation, so its
biological function in inflammatory signaling was investigated in this work. Importantly, here we report a novel distinguishing activity of ASB17 showing that it functions as a ubiquitination inhibitor in regulation of the NF-κB signal pathway.

Cellular inflammatory signals are generally activated by microbial components via pattern recognition receptors (PRRs) such as toll-like receptors (TLRs), retinoid acid-inducible gene-I (RIG-I)-like receptors, and DNA-recognizing receptors (Kawai and Akira, 2010). TNF receptors and the interleukin-1 receptor (IL-1R) activate the subsequent downstream signaling of inflammation when cytokine ligands are induced (Gabay et al., 2016; Hayden and Ghosh, 2014). Tumor necrosis factor (TNF) receptor-associated factor 6 (TRAF6) functions as a crucial adaptor protein that mediates signaling events from the TLR family, IL-1 receptor, and TNF receptor superfamily (Cao et al., 1996; Chung et al., 2007). Thus, TRAF6 play important roles in the activation process of inflammation and immune response. When these receptors are triggered by their ligands, they activate TRAF6 to exert its E3 Ub ligase activity. TRAF6 forms a ubiquitin-binding enzyme complex with Ubc13 and Uev1A to attach lysine 63 (K63)–linked polyubiquitin chains to the substrates (Deng et al., 2000). TRAF6 also attaches K63-linked polyubiquitin chains to itself, which is required for triggering the activation of canonical NF-κB (Lamothe et al., 2008). TRAF6 attached with K63-linked polyubiquitin can recruit TAK1 and phosphorylate the IκB kinase complex IKKα/β/γ, leading to NF-κB activation (Deng et al., 2000). The TRAF6-mediated NF-κB signal pathway is involved in multiple pathological processes and especially essential for inflammatory diseases, which makes TRAF6 become a key modulating target of inflammation (Dainichi et al., 2019). TRAF6 can be ubiquitylated by a K48-linked polyubiquitin form, which leads to its proteasomal degradation. BICP0 and TRIM38 negatively regulate TRAF6-mediated NF-κB by promoting the K48-linked ubiquitination and degradation of TRAF6 (Zhao et al., 2012; Cao et al., 2019). Given the significant relevance of TRAF6-mediated NF-κB in inflammation activation, the modulation on TRAF6 can determine the pathological process of many inflammatory diseases (Du et al., 2017; Lv et al., 2018; Matsumoto et al., 2018; Wu et al., 2020). In this study, we recognize ASB17 as a TRAF6-stabilizing factor which enhances LPS-induced NF-κB activation. ASB17 facilitates the induction of pro-inflammatory cytokines via suppressing TRAF6 K48-linked ubiquitination. These will provide more knowledge about the TRAF6-mediated NF-κB signal pathway.

MATERIALS AND METHODS

Animal Study
Asb17 deficiency mice with the Asb17 Exon 1 (1,595 bp) deleted were reserved by our laboratory (Yang et al., 2021). All animal experiments were approved by the Institutional Animal Care and Use Committee (IACUC) of the College of Life Sciences, Wuhan University (permit number: WDSKY0201901).

Cells
THP-1 (human myeloid leukemia mononuclear cell line) and HEK293T (human embryonic kidney cell line) were purchased from the China Center of Type Culture Collection (CCTCC) (Wuhan, China). HEK293T cells were cultured in DMEM purchased from Gibco (Grand Island, NY, USA) supplemented with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 μg/ml streptomycin sulfate. THP-1 cells were cultured in RPMI 1640 and purchased from Gibco supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin sulfate. Bone marrow-derived dendritic cells (BMDCs) were isolated from the femoral and tibia bone marrow of 6–8-week-old mice. Briefly, the bone marrow was flushed with RPMI 1640. Extracted cells were respersed and passed through a 200-pore-sized mesh. Collectsed cells were respersed in BMDC culture medium, which was made from RPMI 1640 medium containing 10% FBS, 100 U/ml streptomycin, 100 U/ml penicillin, and 20 ng/ml recombinant mouse granulocyte macrophage-colony stimulating factor (GM-CSF) in a 100-mm Petri dish. On the third day, 10 ml BMDC culture medium was added into the Petri dish. On the sixth and eighth days, the medium was changed in half: the old culture medium was collected and centrifuged, and the cell pellet was respersed in the complete medium containing 20 ng/ml recombinant mouse GM-CSF, and then the cell suspension was returned to the original dish. On the tenth day, the culture medium was gently pipetted to collect the suspended cells and centrifuged at room temperature. The supernatant was discarded, while the cell pellet was respersed in complete medium containing 10 ng/ml recombinant mouse GM-CSF and then spread on a cell culture plate at 37°C and 5% CO2.

Bone marrow-derived macrophages (BMDMs) were isolated from the bone marrow of 6–8-week-old mice; these experiments were performed as described previously (Wan et al., 2019). Briefly, the bone marrow was flushed with RPMI 1640. Collected cells were respersed and passed through a 200-pore sized mesh. Collected cells were respersed with Red Blood Cell Lysis Buffer for 5 min, then collected cells were cultured in DMEM complemented with 10% FBS, 10%–20% L929 cell-conditioned medium, 100 μg/ml streptomycin sulfate, and 100 U/ml penicillin for 5–6 days.

Reagents
Lipopolysaccharide (LPS) (Cat# L2630) and polybrene (Cat# TR-1003-G) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Puromycin (Cat# ant-pr-1) was purchased from InvivoGene Biotech Co., Ltd. (San Diego, CA, USA). Cycloheximide (CHX) was purchased from Selleck (Houston, TX, USA). Protease Inhibitor Cocktail Tablets were purchased from Roche (Indianapolis, IN, USA). TRIZol reagent and Lipofectamine 2000 transfection reagent (Cat# 11668019) were purchased from Invitrogen (Carlsbad, CA, USA). Mouse GM-CSF (Cat#315-03) were purchased from PeproTech (Rocky Hill, NJ, USA).

Antibodies
Anti-IRAK1 (D51G7) (Cat#4504), anti-TRAF6 (D21G3) (Cat#8028), anti-Myc (9B11) (Cat#2276), anti-ubiquitin
immunoblotted with the indicated antibodies. In 50 µl 2× SDS loading buffer. All targeted protein bands were reconstituted in 50 mM EDTA, and 5% (vol/vol) glycerol) and then reconstituted (Cat# A22120) and anti-Mouse IgG DyLight 649 (Cat# 66498-1-lg) purchased from Proteintech (Wuhan, Hubei, China). Anti-Rabbit IgG FITC (Cat# F3165) and anti-HA (Cat# H6908) antibodies were purchased from Abcam (Cambridge, MA, USA). Anti-Flag (p65 (Ser536) (Cat#3033) were purchased from Cell Signaling (D7A11) (Cat#5621), anti-p65 (Cat#8242), and anti-phospho-p65 (Ser536) (Cat#3936), anti-K48-linkage-specific polyubiquitin (D9D5) (Cat#8081), anti-K63-linkage-specific polyubiquitin (D7A11) (Cat#5621), anti-p65 (Cat#8242), and anti-phospho-p65 (Ser536) (Cat#3033) were purchased from Cell Signaling Technology (Beverly, MA, USA). Anti-TRAF6 (Cat# ab137452) was purchased from Abcam (Cambridge, MA, USA). Anti-Flag (Cat# F3165) and anti-HA (Cat# H6908) antibodies were purchased from Sigma-Aldrich. Anti-Rabbit IgG FITC (Cat# A22120) and anti-Mouse IgG DyLight 649 (Cat# A23610) antibodies were purchased from Abbkine.

Plasmids and Constructions
Candidate genes were cloned into pcDNA3.1(+)-3Flag vector or pCAGGS-HA vector. TRAF2, TRAF3, TRAF5, TRAF6, IRF7, STING, IRF3, TBK1, and ASB17 were cloned into the pcDNA3.1 (+)-3Flag vector. NLRP3-PYD, ASB17, and NLRP3 were cloned into the pCAGGS-HA vector. NLRP3 point mutant and truncated ASB17 genes were cloned into the pcDNA3.1-3Flag vector. All recombinant plasmids were confirmed by DNA sequencing.

Western Blot Analysis
For Western blot analysis, cells were lysed in lysis buffer. Cell lysates were separated by 7.5%–10% SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred onto a nitrocellulose (NC) membrane. The membranes were sealed in phosphate-buffered saline with 0.1% Tween 20 (TBST) containing 5% non-fat dried milk for 45 min at room temperature (RT) and then were incubated with first antibodies at 4°C overnight. Next, the membranes were incubated with second antibodies for 45 min at RT. Finally, the membranes were detected with the Clarity™ Western ECL Substrate (Bio-Rad).

Co-Immunoprecipitation
The cells were washed with pre-cold PBS for three times and lysed in RIPA lysis buffer (50 mM Tris–HCl (pH 7.4), 150 mM NaCl, 1% (vol/vol) NP-40, 1 mM EDTA, and 5% (vol/vol) glycerol) containing protease inhibitor cocktails. After 20 min, the lysed samples were centrifuged for 10 min at 4°C. A part of the lysates was saved as control. For immunoprecipitation, the rest of the lysates were incubated with the indicated antibodies at 4°C overnight and then incubated with protein G agarose for 2 h. The beads were washed for 5–7 times by RIPA washing buffer (50 mM Tris–HCl (pH 7.4), 300 mM NaCl, 1% (vol/vol) NP-40, 1 mM EDTA, and 5% (vol/vol) glycerol) and then reconstituted in 50 µl 2× SDS loading buffer. All targeted protein bands were immunoblotted with the indicated antibodies.

Quantitative PCR
Total RNA was extracted with TRIzol reagent, following the manufacturer’s instructions. The mRNA was then used to create cDNA by using the M-MLV Reverse Transcriptase (Promega). Real-time quantitative RT-PCR was performed by using SYBR Green PCR Master Mix in the Roche LC480 following the manufacturer’s instructions. All real-time PCR primers were designed in Nucleotide of National Center for Biotechnology Information (NCBI). The following primers were used:

| Gene      | Forward Primer (5′-3′) | Reverse Primer (5′-3′) |
|-----------|-----------------------|-----------------------|
| GAPDH     | human                   | human                 |
| IL-1β     | human                   | human                 |
| IL-6      | human                   | human                 |
| CCL2      | human                   | human                 |
| ASB17     | human                   | human                 |
| IP-10     | human                   | human                 |
| GAPDH     | human                   | human                 |
| IL-1β     | human                   | human                 |
| IL-6      | human                   | human                 |
| CCL2      | human                   | human                 |
| ASB17     | human                   | human                 |
| IP-10     | human                   | human                 |

Lentiviral Production and Infection
The pLenti-CMV vector was derived from the pLenti-CMV-GFP-Puro vector (Addgene, 17448). 3Flag-ASB17 (human) and 3Flag-Asb17 (mouse) were cloned and constructed into pLenti-CMV to generate lentiviruses. pLenti-3Flag-ASB17 (or pLenti-3Flag-Asb17), pMD2.G, and psPAX2 plasmids were co-transfected into HEK293T cells to generate lentivirus. HEK293T cell supernatants were harvested at 36 and 48 h after transfection. The culture supernatants were filtered through a 0.45-µm filter. THP-1 cells were infected with the lentivirus plus 8 µg/ml polybrene for 24–36 h. Next, 1 µg/ml puromycin was added into the culture supernatants for selection of THP-1 stably expressing ASB17 cells. After 5–7 days, THP-1 stably expressing ASB17 cells were identified by qPCR and immunoblot analysis.

Immunofluorescence Microscopy
For immunofluorescence staining, the cells were washed three times with pre-cold PBS and fixed with 4% paraformaldehyde for 15 min. Then, the cells were permeabilized with PBS containing 0.5% Triton X-100 for 5 min and then blocked with PBS containing 5% bovine serum albumin (BSA) for 45 min at room temperature. Then, the cells were incubated with the indicated antibody at 4°C overnight, followed by incubation with anti-Mouse IgG DyLight 649 and anti-Rabbit IgG FITC at room temperature for 2 h. After washing three times, the cells were incubated with DAPI for 5 min in 37°C. Finally, the cells were analyzed using a confocal laser scanning microscope (FluoView FV1000; Olympus, Tokyo, Japan).
In Vivo Ubiquitination Assay
Cells were lysed with 100 µl lysis buffer. After heating at 95°C for 5 min, lysates were diluted 10-fold with dilution buffer containing protease inhibitors. A part of the lysates was saved as input, and the rest of the lysates were immunoprecipitated with indicated antibodies. The rest of the procedures followed the Co-IP assays.

Statistical Analyses
All experiments were reproducible and each set was repeated at least three times. For data with a normal distribution and homogeneity of variance, differences between two groups were statistically analyzed by a two-tailed Student’s t-test. Statistical significance was valued based on the p value. * indicates $p < 0.05$; ** indicates $p < 0.01$; and *** indicates $p < 0.001$. $p < 0.05$ was considered statistically significant.

RESULTS
ASB17 Deficiency Inhibits LPS-Mediated NF-κB Activation in BMDCs
The detection of Asb17 in mouse organs displayed that it mainly expressed in testis (Kim et al., 2004). However, the expression of this gene was detectable in bone marrow-derived macrophages (BMDMs) and dendritic cells (BMDCs) (Figure 1A). Especially,
its expression level in BMDCs could be induced by LPS which was an important pyrogen derived from gram-negative bacteria (Figure 1B). These results indicated that ASB17 might have participated in pathological processes of infectious inflammation. We isolated BMDCs from Asb17−/− and wild-type mice (Figure 1C). We found that Asb17 knocking-out significantly impaired the expression of the LPS-induced pro-inflammatory cytokines Ccl2, Il-6, Il-1β, and Ip-10 in BMDCs (Figures 1D–G). The NF-κB signal pathway plays a critical role in the production of the pro-inflammatory cytokines when TLR4 was activated by LPS (Guha and Mackman, 2001). By detecting this pathway, we found that Asb17 deficiency obviously decreased the phosphorylation of NF-κB p65 when BMDCs were stimulated with LPS (Figure 1H), indicating an impairment of NF-κB activation. In addition, we checked the induction of pro-inflammatory cytokines and the phosphorylation of NF-κB p65 when Asb17 was overexpressed in Asb17−/− BMDCs to verify its specificity. Asb17 overexpression in Asb17−/− BMDCs recovered the LPS-induced Ccl2 and Il-6 expression and NF-κB p65 activation (Figures 1I–K). Our results suggested that ASB17 was important for LPS-mediated NF-κB activation.

Overexpression ASB17 Promotes LPS-Mediated NF-κB Activation in THP-1 Cells
To further examine the role of ASB17 in NF-κB signaling, we constructed THP-1 cells stably expressing ASB17 protein (Figure 2A). Overexpression of ASB17 significantly promoted the expression of IL-6, CCL2, IL-1β, and IP-10 whether with LPS stimulation or not (Figures 2B–E). Besides, ASB17 overexpression obviously enhanced the p65 and IKKα phosphorylation induced by LPS (Figure 2F). Overall, ASB17 could enhance LPS-mediated NF-κB activation.

ASB17 Interacts With TRAF6
To study how ASB17 regulated the NF-κB signal pathway, we screened key molecules involved in or related to this pathway including IRF7, STING, TBK1, IRF3, IκBα, IKKα, RIP1, TRAF6, P50, and P65 by immunoprecipitation to identify which of them might interact with ASB17. Among these molecules, we found that only TRAF6 was associated with ASB17 (Figure 3A). To assure that TRAF6 was associated with ASB17 truly and specifically, we also constructed TRAF family-related genes, TRAF2, TRAF3, and TRAF5, to perform the immunoprecipitation. The results indicated that TRAF6 could be precipitated by ASB17 specifically (Figure 3B). The further co-immunoprecipitation (Co-IP) and reciprocal Co-IP assays confirmed the interaction of ASB17 and TRAF6 (Figures 3C–E). To further confirm the interaction between ASB17 and TRAF6, we identified the interaction in THP-1 cells stably expressing ASB17 protein. The results indicated that ASB17 could interact with endogenous TRAF6 (Figure 3F). This interaction was enhanced by LPS treatment.
Confocal microscopy showed that ASB17 co-localized with TRAF6 (Figure 3G). We also used the bimolecular fluorescence complementation (BiFC) analysis system to detect this protein–protein interaction. We constructed the VN-173-TRAF6 and VC-155-ASB17 plasmids and transfected them into cells. Fluorescence was not observed in control groups but was obviously observed in the experimental group in which VN-173-TRAF6 and VC-155-ASB17 were both transfected. The result suggests that ASB17 directly interacted with TRAF6 (Figure 3I). Overall, these results demonstrated that ASB17 was physically associated with TRAF6. Given that TRAF6 plays a key role in NF-κB signal transduction, we hypothesize that ASB17 regulated the NF-κB signal pathway via the interaction with TRAF6.

**ASB17 Suppresses TRAF6 Polyubiquitination and Stabilizes TRAF6 Protein**

To explore how ASB17 affected the function of TRAF6, we investigated the TRAF6 protein levels. HEK293T were quantitatively transfected with TRAF6, EGFP (set as control), and different doses of ASB17. The Western-blotting analysis displayed that ASB17 increased the TRAF6 protein level but did not affect the EGFP (Figure 4A). To study the stability of TRAF6 protein, we performed a protein decay assay with cycloheximide (CHX) which blocked cellular protein synthesis. The results showed that ASB17 overexpression markedly reduced the decay rate of TRAF6 protein, indicating that ASB17 stabilized the TRAF6 protein (Figure 4B).
Then, we examined whether polyubiquitination of TRAF6 was regulated by ASB17. In HEK293T cells, ASB17 could markedly suppress the polyubiquitination of TRAF6 (Figure 4C). Moreover, ASB17 suppressed the polyubiquitination of TRAF6 in an ASB17 dose-dependent manner (Figure 4D). It had been reported that many E3 ubiquitin ligases targeted ubiquitin chains of linkages (K48-linked or K63-linked) to TRAF6 (Zhang et al., 2013; Wu et al., 2017). We constructed ubiquitin mutant vectors K48O and K63O (all lysine residues become arginine residues except its lysine residues at positions 48 and 63, respectively). The ubiquitin detection displayed that ASB17 could markedly suppress K48-linked polyubiquitination (Figure 4E). To further assure that ASB17 inhibited the K48-linked polyubiquitination of TRAF6, we showed the result that ASB17 could suppress K48-linked polyubiquitination of TRAF6 in an ASB17 dose-dependent manner (Figure 4F). Additionally, overexpression of ASB17 also elevated the endogenous TRAF6 protein level in THP-1 (Figure 4G). Overexpression of ASB17 significantly inhibited the TRAF6 polyubiquitination and K48-linked polyubiquitination in LPS-stimulated THP-1, but no obvious inhibition on the K63-linked polyubiquitination was observed when THP-1 was stimulated with LPS (Figure 4H). In order to confirm the specificity of ASB17-mediated TRAF6 deubiquitination by LPS stimulation, we verified whether the ubiquitination of IRAK1 could be altered by ASB17...
after LPS stimulation. The results indicated that ASB17 did not reduce the ubiquitination of IRAK1 (Figure 4I). Consistent with this, Asb17 knocking-out reduced the endogenous Traf6 protein level and increased the Traf6 polyubiquitination in BMDCs (Figures 4J, K). Together, ASB17 could suppress the polyubiquitination of Traf6, indicating that ASB17 protected Traf6 from degradation to promote NF-kB activation.

The aa177–250 Segment of ASB17 Is Required for the Interaction With the Zn Finger Domain of Traf6 and Polyubiquitination Suppression of Traf6

Traf6 contains an RF domain, a ZnF domain, and a Traf-C domain (Figure 5A). The Co-IP assay indicated that ASB17 could interact with the ZnF domain of Traf6 (Figure 5B). In order to identify the interaction between ASB17 and the specific domain of Traf6, we constructed more detailed domains (Figure 5C). The Co-IP assay also indicated that ASB17 could interact with the ZnF domain of Traf6 (Figure 5D). It had been reported that ASB17 mainly contains the ANK box domain and SOCS box domain (Figure 5E). Co-IP assay indicated that the aa177–250 segment of ASB17 between the ANK box domain and the SOCS box domain was required for the interaction with Traf6 (Figure 5F). To further study the effect of the ASB17 interaction on Traf6 polyubiquitination, we performed the ubiquitin detecting assay with the ASB17 truncation. The results indicated that the truncation of the aa177–250 segment removed the polyubiquitination-suppressing activity of ASB17 on Traf6.
We also found that ASB17 could significantly enhance LPS-mediated NF-κB activation and LPS-induced pro-inflammatory cytokines CCL2 and IL-1β, but ASB17 Δ3 could not (Figures 5H–J). These data revealed that ASB17 via its aa177–250 segment interacted with TRAF6 to inhibit TRAF6 polyubiquitination.

**Hypothetical Model for the Role of ASB17 in the TRAF6-Mediated NF-κB Signal Pathway**

ASB17 knocking-out in BMDCs impaired LPS-induced inflammatory cytokine expressions and markedly inhibited the activation of the NF-κB signal pathway. Overexpression of ASB17 elevated the levels of LPS-mediated NF-κB activation and the cytokine expressions in THP-1 cells. We found that ASB17 interacted with TRAF6 and suppressed K48-linked polyubiquitination of TRAF6, by which it stabilizes the TRAF6 protein. The TRAF6 partner role of ASB17 is crucial for LPS-mediated NF-κB activation and the burst of inflammation (Figure 6).

**DISCUSSION**

It is reported that ASB17 is mainly expressed in the testis, and we have found that ASB17 promotes testis cell apoptosis through specifically degrading BCLW and MCL1 (Yang et al., 2021). ASB17 may be a necessary gene for testis development and physiology. However, we found that ASB17 could be induced by LPS in dendritic cells. These indicated that ASB17 might be involved in immune and inflammatory responses. ASB17 promotes NF-κB activation and facilitated the expression of CCL2 and IL-6 when dendritic cells were stimulated with LPS. Thus, we screened the related factors involved in NF-κB signaling to search the target that ASB17 interacts with. We found that ASB17 was associated with TRAF6 and it significantly suppressed the K48-linked linked polyubiquitin of TRAF6. We suggested that ASB17 facilitates NF-κB activation through maintaining the TRAF6 protein stability.

Although ASB17 has E3 ubiquitin ligase activity like other members of the ASB family (Kohroki et al., 2005; Liu et al., 2019; Yang et al., 2021), our data reveal that it also functions as a ubiquitin-inhibiting factor. Therefore, its function is much more than ubiquitin ligase. It is suggested that ASB17 exerts bilateral functions in protein ubiquitination. We speculate that the function of ASB17 may be determined by the interaction site with the target protein. We previously reported that ASB17 induced the ubiquitination of BCLW and MCL1 for proteasomal degradation through its SOCS domain interaction with the two targets (Yang et al., 2021). The segment aa177–aa250 of ASB17 is required for the association with TRAF6 in the immunoprecipitation assay. The biological function of this segment is unclear before. It is between ankyrin repeat and SOCS domains. We define it as a TRAF6-associated domain and speculate that it mediates the ubiquitination-inhibiting activity of ASB17. In fact, it is not surprising that a protein has both deubiquitination and ubiquitination activities. The amino-terminal domain of A20,

**FIGURE 6** | Hypothetical model for the role of ASB17 in the TRAF6-mediated NF-κB signal pathway. ASB17 interacts with TRAF6 and suppresses its K48-linked linked polyubiquitin, which protects TRAF6 from degradation. LPS activates NF-κB signaling through TRAF6 more effectively in wild-type DCs than in ASB17-knocking-out DCs.
as a de-ubiquitinating enzyme, removes lysine-63 (K63)-linked ubiquitin chains from the receptor-interacting protein (RIP), while the carboxy-terminal domain of A20 functions as a ubiquitin ligase by promoting RIP K48-linked polyubiquitination for proteosomal degradation (Wertz et al., 2004). Although ASB17 does not contain a DUB domain, it may regulate ubiquitination of other proteins by recruiting an E3 ligase to block ubiquitination of TRAF6, or recruit a de-ubiquitinase to de-ubiquitate TRAF6.

Actually, there is faultiness in this study. Because of TRAF6 as the target of ASB17 we screened out from a few candidates which was not a global screening, ASB17 might regulate NF-κB signaling through other targets. Thus, it is necessary to knock out TRAF6 in mice or immune cell lines in the future to look into this possibility. Besides, we did not study the role of ASB17 in certain infectious inflammation models, as we focused on the cellular mechanism of NF-κB activation involved in pro-inflammatory cytokine induction. We revealed the biological role of ASB17 in TRAF6/NF-κB signaling. Given the importance of its target TRAF6 in cells, it is worth to study the functions of ASB17 in physiology and pathology by using clinical or animal models.

Therefore, we report a novel function of ASB17 that it targets TRAF6 to suppress its K48-linked polyubiquitination and proteosomal degradation. Besides, we recognize the important role of ASB17 in inflammation that it enhances NF-κB activation by maintaining TRAF6 stability.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding authors.

REFERENCES

Cao, C., An, R., Yu, Y., Dai, H., Qu, Z., Gao, M., et al. (2019). BICP0 Negatively Regulates TRAF6-Mediated NF-kappaB and Interferon Activation by Promoting K48-Linked Polyubiquitination of TRAF6. Front. Microbiol. 10, 3040. doi: 10.3389/fmicb.2019.03040

Cao, Z., Xiong, J., Takeuchi, M., Kurama, T., and Goeddel, D. V. (1996). TRAF6 Is a Signal Transducer for Interleukin-1. Nature 383, 443–446. doi: 10.1038/383443a0

Chen, F. Y., Huang, M. Y., Lin, Y. M., Ho, C. H., Lin, S. Y., Chen, H. Y., et al. (2019). BIK Ubiquitination by the E3 Ligase Cul5-ASB11 Determines Cell Fate During Cellular Stress. J. Cell Biol. 218, 3002–3018. doi: 10.1083/jcb.201901156

Chung, J. Y., Lu, M., Yin, Q., Lin, S. C., and Wu, H. (2007). Molecular Basis for the Unique Specificity of TRAF6. Adv. Exp. Med. Biol. 597, 122–130. doi: 10.1007/978-0-387-70630-6_10

Dainichi, T., Matsumoto, R., Mostafa, A., and Kabashima, K. (2019). Immune Control by TRAF6-Mediated Pathways of Epithelial Cells in the EIMF (Epithelial Immune Microenvironment). Front. Immunol. 10, 1107. doi: 10.3389/fimmu.2019.01107

Deng, L., Wang, C., Spencer, E., Yang, L., Braun, A., You, J., et al. (2000). Activation of the IkappaB Kinase Complex by TRAF6 Requires a Dimeric Ubiquitin-Conjugating Enzyme Complex and a Unique Polyubiquitin Chain. Cell 103, 351–361. doi: 10.1016/S0092-8674(00)00126-4

Du, M., Yuan, L., Tan, X., Huang, D., Wang, X., Zheng, Z., et al. (2017). The LPS-Inducible IncRNA Mirt2 Is a Negative Regulator of Inflammation. Nat. Commun. 8, 2049. doi: 10.1038/s41467-017-02229-1

FUNDING

This work was supported by the National Natural Science Foundation of China (81730061, 32070148, and 81471942), the Guangdong Province “Pearl River Talent Plan” Innovation and Entrepreneurship Team Project (2017ZT075Y580), the Guangdong Basic and Applied Basic Research Foundation (2020A1515010369, 2019A1515011073), and the Fundamental Research Funds for the Central Universities (21620401).

ETHICS STATEMENT

The data curation, Funding acquisition, YL and JW. Data curation, Funding acquisition, YL and JW. Investigation, GL, XIC, QZ, WZ, and QT. Methodology, PW, GW, and SZ. Project administration, YL and JW. Software, ZL, PP, GL, XIC, and QZ. Supervision, JW. Validation, ZL, PP, GL, XIC, and QZ. Visualization, PW, GW, and SZ. Writing—original draft, PW, GW, and SZ. Writing—review and editing, YL and JW. All authors contributed to the article and approved the submitted version.

AUTHOR CONTRIBUTIONS

Conceptualization, PW, GW, YL, and JW. Data curation, GW and SZ Formal analysis, PW, GW, SZ, YZ, YJ, XIC, ZL, and PP. Funding acquisition, YL and JW. Investigation, GL, XIC, QZ, WZ, and QT. Methodology, PW, GW, and SZ. Project administration, YL and JW. Software, ZL, PP, GL, XIC, and QZ. Supervision, JW. Validation, ZL, PP, GL, XIC, and QZ. Visualization, PW, GW, and SZ. Writing—original draft, PW, GW, and SZ. Writing—review and editing, YL and JW. All authors contributed to the article and approved the submitted version.
Liu, P., Verhaar, A. P., and Peppelenbosch, M. P. (2019). Signaling Size: Ankyrin and SOCS Box-Containing ASB E3 Ligases in Action. Trends Biochem. Sci. 44, 64–74. doi: 10.1016/j.tibs.2018.10.003
Lv, Y., Kim, K., Sheng, Y., Cho, J., Qian, Z., Zhao, Y. Y., et al. (2018). YAP Controls Endothelial Activation and Vascular Inflammation Through Tra6. Circ. Res. 123, 43–56. doi: 10.1161/CIRCRESAHA.118.313143
Matsumoto, R., Dainichi, T., Tsuchiya, S., Nomura, T., Kitoh, A., Hayden, M. S., et al. (2018). Epithelial TRAF6 Drives IL-17-Mediated Psoriatic Inflammation. JCI Insight 3 (15), e121175. doi: 10.1172/jci.insight.121175
Uematsu, K., Okumura, F., Tonogai, S., Joo-Okumura, A., Alemayehu, D. H., Nishikimi, A., et al. (2016). ASB7 Regulates Spindle Dynamics and Genome Integrity by Targeting DDA3 for Proteasomal Degradation. J. Cell Biol. 215, 95–106. doi: 10.1083/jcb.201603062
Wan, P., Zhang, Q., Liu, W., Jia, Y., Ai, S., Wang, T., et al. (2019). Cullin1 Binds and Promotes NLRP3 Ubiquitination to Repress Systemic Inflammasome Activation. FASEB J. 33, 5793–5807. doi: 10.1096/fj.201801681R
Wertz, I. E., O'rourke, K. M., Zhou, H., Eby, M., Aravind, L., Seshagiri, S., et al. (2004). De-Ubiquitination and Ubiquitin Ligase Domains of A20 Downregulate NF-KappaB Signalling. Nature 430, 694–699. doi: 10.1038/ nature02794
Wu, Y., Hu, Y., Wang, B., Li, S., Ma, C., Liu, X., et al. (2020). Dopamine Uses the DRD5-ARRB2-PP2A Signaling Axis to Block the TRAF6-Mediated NF-KappaB Pathway and Suppress Systemic Inflammation. Mol. Cell 78, 42–56.e14. doi: 10.1016/j.molcel.2020.01.022
Wu, C., Su, Z., Lin, M., Ou, J., Zhao, W., Cui, J., et al. (2017). NLRP11 Attenuates Toll-Like Receptor Signalling by Targeting TRAF6 for Degradation via the Ubiquitin Ligase RNF19A. Nat. Commun. 8, 1977. doi: 10.1038/s41467-017-02073-3
Yang, G., Wan, P., Xiang, Q., Huang, S., Huang, S., Wang, J., et al. (2021). E3 Ubiquitin Ligase ASB17 Promotes Apoptosis by Ubiquitylating and Degrading BCLW and MCL1. Biol. (Basel) 10 (3), 234. doi: 10.3390/biology10030234
Zhang, X., Zhang, J., Zhang, L., Van Dam, H., and Ten Dijke, P. (2013). UBE2O Negatively Regulates TRAF6-Mediated NF-KappaB Activation by Inhibiting TRAF6 Polyubiquitination. Cell Res. 23, 366–377. doi: 10.1038/cr.2013.21
Zhao, W., Wang, L., Zhang, M., Yuan, C., and Gao, C. (2012). E3 Ubiquitin Ligase Tripartite Motif 38 Negatively Regulates TLR-Mediated Immune Responses by Proteasomal Degradation of TNF Receptor-Associated Factor 6 in Macrophages. J. Immunol. 188, 2567–2574. doi: 10.4049/jimmunol.1103255

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Wan, Yang, Zhang, Zhang, Jia, Che, Luo, Pan, Li, Chen, Zhang, Zhang, Tan, Li and Wu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.